Borthakur, G., Popplewell, L., Boyiadzis, M., Foran, J., Platzbecker, U., Vey, N., . . . Kantarjian, H. (2016). Activity of the oral MEK inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer.
シカゴスタイル引用形Borthakur, Gautam, et al. "Activity of the Oral MEK Inhibitor Trametinib in RAS-mutant Relapsed or Refractory Myeloid Malignancies." Cancer 2016.
MLA引用形式Borthakur, Gautam, et al. "Activity of the Oral MEK Inhibitor Trametinib in RAS-mutant Relapsed or Refractory Myeloid Malignancies." Cancer 2016.
警告: この引用は必ずしも正確ではありません.